Perillyl Alcohol in Preventing Recurrent Breast Cancer in Women Who Have Been Treated With Surgery With or Without Adjuvant Therapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2003 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00022425
First received: August 10, 2001
Last updated: December 17, 2013
Last verified: September 2003

August 10, 2001
December 17, 2013
June 2001
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00022425 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Perillyl Alcohol in Preventing Recurrent Breast Cancer in Women Who Have Been Treated With Surgery With or Without Adjuvant Therapy
Multiple-Dose Phase I and Pharmacokinetic Trial of Perillyl Alcohol

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the recurrence of cancer. The use of perillyl alcohol may be effective in preventing the recurrence of breast cancer.

PURPOSE: Phase I trial to study the effectiveness of perillyl alcohol in preventing the recurrence of breast cancer in women who have been treated with surgery with or without adjuvant therapy.

OBJECTIVES:

  • Determine the maximum tolerated dose of perillyl alcohol in women at risk for recurrent breast cancer.
  • Determine the toxicity of this drug in these patients.
  • Determine the single-dose and multiple-dose pharmacokinetics of this drug in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive oral perillyl alcohol once daily on days 1-28. Treatment continues every 4 weeks for 3 courses.

Cohorts of 6 patients receive escalating doses of perillyl alcohol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience grade 1 toxicity or at least 1 of 6 patients experience grade 2 or greater toxicity.

Patients are followed weekly.

PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.

Interventional
Phase 1
Primary Purpose: Prevention
Breast Cancer
Drug: perillyl alcohol
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Personal history of stage Tis, I, II, or IIIA breast cancer
  • Previously treated with definitive resection with curative intent
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age:

  • Over 18

Sex:

  • Female

Menopausal status:

  • Not specified

Performance status:

  • ECOG 0-1

Life expectancy:

  • Not specified

Hematopoietic:

  • WBC at least 3,000/mm3
  • Platelet count at least 100,000/mm3
  • Hemoglobin at least 9.0 g/dL

Hepatic:

  • Bilirubin no greater than 1.5 mg/dL
  • AST and ALT no greater than 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 1.5 times ULN

Renal:

  • Creatinine no greater than 1.6 mg/dL

Other:

  • No known malabsorption syndrome
  • No contraindication to perillyl alcohol
  • No hypersensitivity to citrus or soybean products
  • No non-breast malignancy within the past 2 years except nonmelanoma skin cancer or carcinoma in situ
  • No active malignancy
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • At least 6 months since prior chemotherapy

Endocrine therapy:

  • Concurrent adjuvant hormonal therapy allowed

Radiotherapy:

  • At least 6 months since prior radiotherapy

Surgery:

  • See Disease Characteristics
  • At least 6 months since prior surgery
  • At least 2 years since prior primary surgery
  • More than 4 weeks since prior surgery requiring general anesthesia, including breast reconstructive surgery

Other:

  • More than 3 months since prior enrollment in a single-dose study of perillyl alcohol
  • More than 3 months since prior enrollment in current study (at a lower dose level)
  • No concurrent vitamin supplements except a daily multivitamin (recommended daily allowance)
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00022425
CDR0000068816, CCF-IRB-3574, CCF-N01-CN-55131, NCI-P01-0189
Not Provided
Not Provided
The Cleveland Clinic
National Cancer Institute (NCI)
Study Chair: George Thomas Budd, MD The Cleveland Clinic
National Cancer Institute (NCI)
September 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP